VEGF Trap-Eye continues to impress

Article

Regeneron Pharmaceuticals and Bayer Healthcare have announced positive preliminary data from a Phase II randomized study of the VEGF Trap-Eye treatment for wet age-related macular degeneration (AMD).

Regeneron Pharmaceuticals and Bayer Healthcare have announced positive preliminary data from a Phase II randomized study of the VEGF Trap-Eye treatment for wet age-related macular degeneration (AMD).

The VEGF Trap-Eye is a fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A and related placental growth factor. A total of 150 subjects were randomized into five groups and treated with the VEGF Trap-Eye in one eye (two groups received either 0.5 or 2.0 mg administered every four weeks; three groups received a single dose of either 0.5, 2.0 or 4.0 mg).

The VEGF Trap-Eye met its primary endpoint of a statistically significant reduction in retinal thickness 12 weeks from baseline. Mean change in visual acuity (VA), a secondary endpoint, also demonstrated a statistically significant improvement with all subjects increasing by a mean of 5.9 letters. No drug-related serious adverse events were reported. The most common adverse events were those typically associated with intravitreal injections.

Regeneron and Bayer will jointly market the VEGF Trap-Eye outside of the Unites States, while Regeneron will maintain exclusive rights in the US. The companies plan to initiate a Phase III study during the second half of 2007.

Related Videos
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Diana Do, MD, Professor of Ophthalmology, Byers Eye Institute, Stanford University, discusses the PHOTON study results as presented AAO
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.